Testing Blood Samples for Proteins Can Reveal Malaria Severity

It remains a challenge to diagnose the disease early and accurately in order to provide timely and effective treatment. With millions of cases and nearly 600,000 deaths annually, the situation is especially dire in regions like Africa, where the disease burden is most severe. Children under five are particularly vulnerable. The ability to predict the severity of the disease and identify high-risk patients early on could greatly improve treatment outcomes. Now, a new study has identified over 250 proteins that are strongly affected by malaria, which could help predict the severity of the disease and allow faster intervention.

The study was conducted by researchers at Karolinska Institutet (Stockholm, Sweden) using blood samples from 72 adult travelers diagnosed with malaria at Karolinska University Hospital. By analyzing these samples, the researchers were able to identify around 700 proteins that changed during the infection, with over 250 of them showing strong effects. This analysis allowed them to map the proteins and group patients according to the severity of the disease. The team employed data-driven techniques to link the proteins to specific immune cells and identify their origins in various organs, providing new insights into the immune system's response to the infection.

The findings, published in Immunity, revealed how these proteins could be used to identify high-risk patients more quickly and enable more effective treatment. This approach provides a detailed understanding of the immune dynamics during malaria and could guide future clinical applications. However, further studies are needed to validate these results in larger patient populations. The researchers aim to explore the potential clinical applications of these protein signatures to enhance malaria diagnostics and treatment.

“Malaria can quickly become life-threatening, but it is difficult to predict at an early stage which patients are at risk of deterioration. Our results show how a set of proteins can help identify high-risk patients more quickly and enable more effective treatment,” said Anna Färnert, professor at Karolinska Institutet.